The Company is founded by Mr. K.P. Menon and Mr.
K.H. Shah. Headquartered in Bombay, India, the company starts
production with a focus on research in anti-TB therapy. In its
first year, Therapeutic introduces a first-time product for
Tuberculosis therapy, ISOPASCAL-CD, an Isoniazid-PAS combination
in tablet form.
Mr K.P.Menon takes over the management of the
company along with his brother Mr. P.P Menon. Therapeutic
continues to operate from Bombay with research continuing on
newer formulations and dosage forms. The company collaborates with Chinoin, Hungary (now Sanofi) to market tetracycline for the Indian market.
For the first time in the world, Paracetamol is
solubilized and presented in an oral dosage form at a strength of
150 mg/ml as Aeknil Drops. Product targeted for pediatric
population. This product then evolved to Aeknil Syrup, which is
Paracetamol 150 mg /5ml in a flavoured syrupy base. Aeknil
tablets also introduced at 500 mg strength.
Aeknil Injection, the first Paracetamol solution
for injection in the world is introduced. Therapeutic's
R&D team responsible for solubilizing and stabilizing
Paracetamol in a convenient injectable form at a never before
strength of 150 mg/ml. Product is very well received by the
medical fraternity and several clinical trials performed with
Aeknil displaces dipyrone as the preferred
Injection for the treatment of pyrexia and analgesia. This was
brought about in view of the safety concerns of Dipyrone. Aeknil
displaces Analgin as the preferred choice due its superior safety
and minimal side effects, especially in pediatric population.
Aeknil range of products makes inroads to the Gulf markets.
Well received in the UAE and Saudi Arabia.